Wednesday, June 1, 2011
EMA accepts Pfizer's filing of axitinib for regulatory review to treat advanced renal cell carcinoma
Pfizer Inc. announced today that the European Medicines Agency has accepted Pfizer's filing for regulatory review of axitinib for patients with advanced renal cell carcinoma after failure of prior systemic treatment.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment